SCHEDULE: Frazier Life Sciences Funds Adjust Aclaris Therapeutics Stake

Frazier Life Sciences entities have filed a Schedule 13G, reporting beneficial ownership of Aclaris Therapeutics, Inc. common stock.

Summary

• This filing is a Schedule 13G, a statement of beneficial ownership, filed by several Frazier Life Sciences entities concerning Aclaris Therapeutics, Inc.
• The filing details the aggregate beneficial ownership of Aclaris Therapeutics, Inc. common stock by these entities.
• The reporting persons are Frazier Life Sciences Public Fund, L.P., FHMLSP, L.P., FHMLSP, L.L.C., Frazier Life Sciences XI, L.P., FHMLS XI, L.P., FHMLS XI, L.L.C., Frazier Life Sciences XII, L.P., FHMLS XII, L.P., and FHMLS XII, L.L.C.
• The total beneficial ownership reported is 7,879,943 shares for Frazier Life Sciences Public Fund, L.P. and its related entities, representing 5.4% of the class.
• Frazier Life Sciences XI, L.P. and its related entities report beneficial ownership of 86,910 shares, representing 0.1% of the class.
• Frazier Life Sciences XII, L.P. and its related entities report beneficial ownership of 762,663 shares, representing 0.5% of the class.
• The percentage of class is calculated based on 147,198,893 shares of Common Stock outstanding on July 31, 2026, as per Aclaris Therapeutics' Form 10-Q filed on August 6, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily serves as a procedural disclosure of beneficial ownership changes rather than providing operational or financial performance updates.

Negatives

• The filing does not contain any operational or financial performance data, making it difficult to assess the company's current health or future prospects based solely on this document.

Future Outlook

This filing does not contain any forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard disclosures for significant institutional investors and do not inherently signal a change in company strategy or performance. The involvement of Frazier Life Sciences, a prominent venture capital firm in the life sciences sector, indicates continued institutional interest in Aclaris Therapeutics.

Stakeholder Impact

• Shareholders may note the continued significant stake held by Frazier Life Sciences entities, which can be interpreted as a sign of confidence in the company's long-term prospects, although this filing provides no direct performance indicators.

Key Dates

Keywords

beneficial ownership, Schedule 13G, Frazier Life Sciences, Aclaris Therapeutics, common stock, investment fund